Type of security: Stock
Sector: Health Care
Market Capitalization: 27.15 M
The data is delayed by 15 minutes.
Description: Cleveland BioLabs, Inc., a biopharmaceutical company, focuses on developing pharmaceuticals designed to address diseases with significant medical need. Its lead drug candidates include Entolimod, which is being developed as radiation countermeasure for prevention of death from acute radiation syndrome and as an oncology drug; and CBL0137, which is in two multi-center, single agent, dose escalation Phase I studies in subjects with advanced solid tumors. The company?s clinical stage product candidates comprise CBL0102, which has completed Phase I safety and tolerability study in patients with liver metastases of solid tumors of epithelial origin, or primary advanced hepatic carcinoma; and Entolimod, which is in Phase I clinical trials for open-label, dose-escalation study designed to evaluate the safety, pharmacokinetics, pharmacodynamics, and clinical activity in advanced cancer patients. Its preclinical stage product candidates include CBLB612, a pharmacologically optimized synthetic molecule that structurall
|Shares Outstanding||10.99 M||EPS||-0.33||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||8.01%||Sales Growth - Q/Q||-56.33%||P/E||-9.91|
|P/E To EPS Growth||P/S||9.13||P/BV||-4.97||Price/Cash Per Share|
|Price/Free Cash Flow||-1.88||ROA||-4.07%||ROE||7.97%||ROI|
|Current Ratio||0.52||Quick Ratio||Long Term Debt/Equity||-0.25||Debt Ratio||-1.97|
|Gross Margin||Operating Margin||-478.01%||Net Profit Margin||-14.63%||Dividend Payout Ratio|
|Cash From Financing Activities||3.31 M||Cash From Investing Activities||40 K||Cash From Operating Activities||-2.23 M||Gross Profit|
|Net Profit||-3.65 M||Operating Profit||-3.31 M||Total Assets||10.68 M||Total Current Assets||5.58 M|
|Total Current Liabilities||10.76 M||Total Debt||4.06 M||Total Liabilities||16.14 M||Total Revenue||610 K|
|High 52 week||3.6||Low 52 week||1.01||Last close||1.44||Last change||-6.66%|
|RSI||36.13||Average true range||0.11||Beta||0.87||Volume||56.99 K|
|Simple moving average 20 days||-8.13%||Simple moving average 50 days||-7.12%||Simple moving average 200 days||-26.49%|
|Performance Week||0%||Performance Month||-15.29%||Performance Quart||2.13%||Performance Half||-39.5%|
|Performance Year||-58.74%||Performance Year-to-date||42.57%||Volatility daily||4.34%||Volatility weekly||9.7%|
|Volatility monthly||19.87%||Volatility yearly||68.83%||Relative Volume||204.46%||Average Volume||23.82 K|
|New High||New Low|
2019-06-12 10:30:11 | Is Cleveland BioLabs, Inc. NASDAQ:CBLI Overpaying Its CEO?
2019-05-25 08:15:00 | M&T Bank crossed $4 billion revenue mark to remain top Buffalo-based public company
2019-05-15 08:30:00 | Cleveland Biolabs Reports First Quarter 2019 Financial Results and Development Progress
2019-03-07 08:15:00 | Cleveland Biolabs Reports 2018 Financial Results and Development Progress
2019-02-07 11:58:22 | Does Cleveland BioLabs, Inc. NASDAQ:CBLI Have A Particularly Volatile Share Price?
2018-12-14 14:22:54 | Genome Protection received $10.5M investment from fund controlled by Roman Abramovich
2018-12-06 09:31:48 | What does Cleveland BioLabs Inc’s NASDAQ:CBLI Balance Sheet Tell Us About Its Future?
2018-11-23 07:20:00 | Market Trends Toward New Normal in support, Innovative Solutions and Support, Cleveland BioLabs, Ideal Power, Comstock Holding Companies, and GWG — Emerging Consolidated Expectations, Analyst Ratings
2018-11-14 07:30:00 | Cleveland Biolabs Reports Third Quarter 2018 Financial Results and Development Progress
2018-10-05 13:24:20 | The Cleveland BioLabs Inc NASDAQ:CBLI Ownership Structure Could Be Important
2018-08-14 17:15:00 | Cleveland Biolabs Reports Second Quarter 2018 Financial Results And Development Progress
2018-08-14 16:45:00 | Cleveland Biolabs Announces Formation and Financing of an Anti-Aging Joint Venture
2018-06-22 15:12:42 | Ikea’s departure from Cary leads to impairment charge for mall owner
2018-05-31 16:18:19 | Should You Be Concerned About Cleveland BioLabs Inc’s NASDAQ:CBLI Investors?
2018-05-15 08:00:00 | Cleveland Biolabs Reports First Quarter 2018 Financial Results and Development Progress
2018-04-17 14:37:18 | Is Cleveland BioLabs Inc’s NASDAQ:CBLI CEO Being Overpaid?
2018-03-28 17:05:00 | Cleveland Biolabs Announces Progress on European Marketing Authorization Application
2018-03-06 08:00:00 | Cleveland Biolabs Reports 2017 Financial Results and Development Progress
2018-02-21 16:28:24 | Should You Be Concerned About Cleveland BioLabs Inc’s NASDAQ:CBLI Investors?
2018-01-01 14:45:08 | Is Cleveland BioLabs Inc’s NASDAQ:CBLI CEO Incentives Align With Yours?
2017-12-29 11:40:01 | ETFs with exposure to Cleveland BioLabs, Inc. : December 29, 2017
2017-12-13 12:55:24 | ETFs with exposure to Cleveland BioLabs, Inc. : December 13, 2017
2017-11-30 13:36:58 | ETFs with exposure to Cleveland BioLabs, Inc. : November 30, 2017
2017-11-22 20:40:34 | What Does Cleveland BioLabs Inc’s CBLI Ownership Structure Look Like?
2017-11-15 11:38:44 | ETFs with exposure to Cleveland BioLabs, Inc. : November 15, 2017
2017-11-14 08:15:00 | Cleveland BioLabs Reports Third Quarter 2017 Financial Results and Development Progress
2017-11-08 16:49:16 | How Does Cleveland BioLabs Inc CBLI Compare To The Healthcare Sector?
2017-10-26 10:23:40 | ETFs with exposure to Cleveland BioLabs, Inc. : October 26, 2017
2017-10-11 11:17:18 | ETFs with exposure to Cleveland BioLabs, Inc. : October 11, 2017
2017-09-19 17:11:58 | ETFs with exposure to Cleveland BioLabs, Inc. : September 19, 2017
2017-09-11 15:57:10 | What You Must Know About Cleveland BioLabs Inc’s CBLI Risks
2017-08-04 19:26:23 | ETFs with exposure to Cleveland BioLabs, Inc. : August 4, 2017
2017-07-12 14:18:45 | ETFs with exposure to Cleveland BioLabs, Inc. : July 12, 2017
2017-06-26 15:32:39 | ETFs with exposure to Cleveland BioLabs, Inc. : June 26, 2017
2017-06-16 15:31:12 | ETFs with exposure to Cleveland BioLabs, Inc. : June 16, 2017
2017-06-05 14:06:59 | ETFs with exposure to Cleveland BioLabs, Inc. : June 5, 2017
2017-05-15 07:30:00 | Cleveland BioLabs Reports First Quarter 2017 Financial Results and Development Progress
2017-04-20 08:00:00 | Governments Looking at Cleveland Biolabs Radiation Countermeasure
2017-04-19 14:14:28 | ETFs with exposure to Cleveland BioLabs, Inc. : April 19, 2017
2017-04-17 07:36:35 | Cleveland BioLabs Announces Commencement of In Vivo Biocomparability Study